Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain... Show more
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PTIR | 22.17 | 1.53 | +7.41% |
| GraniteShares 2x Long PLTR Daily ETF (PTIR) | |||
| SHPP | 33.91 | N/A | N/A |
| Pacer Industrials and Logistics ETF (SHPP) | |||
| SMIG | 31.45 | -0.06 | -0.21% |
| Bahl & Gaynor Small/Mid Cap Income Growth ETF (SMIG) | |||
| EGUS | 59.07 | -0.69 | -1.15% |
| iShares ESG Aware MSCI USA Growth ETF (EGUS) | |||
| IGI | 15.95 | -0.31 | -1.91% |
| Western Asset Investment Grade Opportunity Trust Inc | |||
A.I.dvisor indicates that over the last year, SER has been loosely correlated with GERN. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SER jumps, then GERN could also see price increases.
| Ticker / NAME | Correlation To SER | 1D Price Change % | ||
|---|---|---|---|---|
| SER | 100% | -5.19% | ||
| GERN - SER | 65% Loosely correlated | -5.34% | ||
| XTLB - SER | 59% Loosely correlated | +2.27% | ||
| ELVN - SER | 37% Loosely correlated | -4.36% | ||
| TOVX - SER | 34% Loosely correlated | +1.69% | ||
| LIFE - SER | 34% Loosely correlated | -6.30% | ||
More | ||||
On September 22, 2026, the Stochastic Oscillator for SER moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 71 instances where the indicator left the oversold zone. In 68 of the 71 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
The 50-day moving average for SER moved above the 200-day moving average on September 03, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +4.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where SER advanced for three days, in 168 of 202 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
SER may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 10-day RSI Indicator for SER moved out of overbought territory on August 18, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In 16 of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SER as a result. In 108 of 121 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for SER turned negative on August 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 50 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
SER moved below its 50-day moving average on September 15, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SER crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SER declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for SER entered a downward trend on September 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.970) is normal, around the industry mean (26.046). P/E Ratio (1.630) is within average values for comparable stocks, (40.021). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.064). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (204.082) is also within normal values, averaging (436.793).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. SER’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SER’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.